Skip to content

The Role of DNA Damage of Granulosa Cell on Oocyte Quality and in Vitro Fertilization Outcome

The Role of DNA Damage of Granulosa Cell on Oocyte Quality and in Vitro Fertilization Outcome

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03345030
Enrollment
60
Registered
2017-11-17
Start date
2017-05-09
Completion date
2018-03-30
Last updated
2017-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

in Vitro Fertilization

Keywords

comet assay, DNA damage, granulosa, IVF outcome

Brief summary

Deoxyribonucleic acid (DNA) damage of granulosa cells obtained during oocyte retrieval will be evaluated by comet assay in unexplained infertile patients undergoing in vitro fertilization (IVF) treatment. The oocytes will be graded by particular criteria. Fertilization, embryo quality, transfer rate, implantation, clinical pregnancy, pregnancy outcomes (gestational age at delivery, route of delivery, and birthweight etc.) will be recorded as well as demographic data. DNA damage of granulosa cells will be compared between unexplained infertile and control groups. The effect of DNA damage of granulosa cells on fertilization, quality of oocyte and embryo, implantation, and clinical pregnancy will be also evaluated.

Detailed description

Granulosa cells surrounding the oocytes will be mechanically obtained during the oocyte pick-up procedure in women undergoing in vitro fertilization (IVF) treatment due to unexplained infertility. Deoxyribonucleic acid (DNA) damage in these cells will be evaluated by comet assay. The quality of oocytes retrieved during the oocyte pick-up procedure will be graded by particular criteria (zona pellucida thickness, granulation, vacuolization, etc). Fertilization rates, embryo quality by grading, and transfer rates will also be assessed. Implantation and clinical pregnancy rates, and pregnancy outcomes including gestational age at delivery, route of delivery, and birthweight will be recorded as well as demographic data such as age, body-mass index, smoking, alcohol use, employment, coexisting chronic disease, infertility duration, etiology of infertility, treatment protocol, and hormone levels on day 3. Implantation will be evaluated by determination of serum human chorionic gonadotropin (hCG) at day 12 following an embryo transfer. Clinical pregnancy will be diagnosed upon presence of gestational sac on ultrasound examination. DNA damage of granulosa cells will be compared between unexplained infertile group and control group. The effect of DNA damage of granulosa cells on fertilization, quality of oocyte and embryo, implantation, and clinical pregnancy will be also evaluated.

Interventions

None listed

Sponsors

Suleyman Demirel University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
19 Years to 44 Years
Healthy volunteers
Yes

Inclusion criteria

* Unexplained infertile patients undergoing in vitro fertilization (IVF) treatment

Exclusion criteria

1. Chronic systemic disease (rheumatoid arthritis, hypertension, diabetes..) 2. Endocrinopathy (Thyroid, prolactin... abnormalities) 3. Chemotherapy or radiotherapy history 4. Cigarette, alcohol, chronic medication use 5. Diminished ovarian reserve 6. Endometriosis 7. Having any medication use 8. History of any surgical procedure on ovaries and uterus 9. Smoking or alcohol consumption 10. Severe oligoasthenospermia 11. Tubal infertility associated with hydrosalpinx, severe pelvic adhesions, endometriosis or pelvic inflammatory disease

Design outcomes

Primary

MeasureTime frameDescription
Clinical pregnancy defined as the presence of gestational sac in transvaginal ultrasonographic examination 5 weeks after embryo transfer5 weeks after embryo transferPresence of a gestational sac in transvaginal ultrasonographic examination

Secondary

MeasureTime frameDescription
Fertilization defined as the presence of two pronuclei under light microscope one day after intracytoplasmic sperm injection procedure1 day after intracytoplasmic sperm injection procedurePresence of two pronuclei under light microscope
Oocyte grade assessed by four parameters (cytoplasmic granulation, properties of the polar body, the perivitelline space and properties of the zona pellucida) under invert microscope 36 hours after human chorionic gonadotropin administration36 hours after human chorionic gonadotropin administrationOocytes were graded by particular criteria including cytoplasmic granulation, properties of polar body, perivitellin space and zona pellucida. Central cytoplasmic granulation=0, homogenous cytoplasmic granulation=1; large fragmented polar bodies=0, non-fragmented polar bodies with normal size=1; presence of debris in perivitellin space=0, absence of debris in perivitelline space=1; \>15 mm thickness and rough surfaced zona pellucida=0, \<15 mm thickness and smooth surface zona pellucida=1. A total of used 3-4 points were considered as Grade 1 oocytes (best quality), 2-3 points were grade 2 (moderate quality), 0-1 points were considered as grade 3 (poor quality).
Embryo grade assessed under invert microscope 3 days after intracytoplasmic sperm injection procedure3 days after intracytoplasmic sperm injection procedureThe quality of embryos was graded from 1 to 3 under inverted microscope 3 days after intracytoplasmic sperm injection procedure. Embryos with even-sized blastomers and/or \<5% fragments were classified as Grade 1 (good quality). Grade 2 embryos (moderate quality) had blastomeres with slightly-moderate size differences and/or 5-50% fragments. Grade 3 embryos (poor quality) had markedly different-sized blastomers and/or \>50% fragments.
Implantation defined as positive serum human chorionic gonadotropin levels 12 days after embryo transfer12 days after embryo transferPositive human chorionic gonadotropin levels

Countries

Turkey (Türkiye)

Contacts

Primary ContactESRA NUR TOLA
perinatalog@hotmail.com+90 5327921084

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026